Neurofilament Light Chain Blood Test: What You Need to Know

A neurofilament light chain (NfL) blood test measures a structural protein that leaks out of damaged nerve cells, providing a window into whether your brain or nerves are being injured. The test has become one of the most studied blood biomarkers in neurology over the past decade, with applications spanning multiple sclerosis, Alzheimer’s disease, ALS, concussion, and more. It is not a test that diagnoses a single disease. Instead, it acts something like a smoke alarm for the nervous system: it tells you damage is happening, but not which room is on fire.

What Neurofilament Light Chain Actually Is

Neurofilaments are long, thread-like proteins that form the internal scaffolding of nerve cells. They are part of the structural skeleton of neurons, particularly abundant in axons, the long cables that carry electrical signals from one neuron to the next. Their job is to maintain the size, shape, and mechanical strength of those cables. Neurofilament light chain is the smallest of the neurofilament subunits and turns out to be the one most reliably detected in blood after nerve injury.

When neurons are damaged, whether by disease, trauma, or inflammation, the internal scaffolding breaks apart. A calcium-dependent enzyme called calpain chops up the neurofilament proteins, and the fragments spill out of the cell. Research shows that the majority of this released NfL is free-floating rather than packaged in tiny vesicles, meaning it escapes directly into the surrounding fluid and eventually makes its way into the bloodstream.

¹ The more nerve damage occurring at any given moment, the higher the NfL concentration in your blood. That relationship is what makes the test useful, but also what makes it nonspecific.

How the Blood Test Works

NfL concentrations in blood are extremely low, on the order of single-digit to double-digit picograms per milliliter in healthy people. Traditional lab tests cannot detect amounts that small. The breakthrough came with ultrasensitive immunoassay platforms, most prominently a technology called Simoa (Single Molecule Array), which can detect individual protein molecules one at a time. Simoa’s sensitivity made reliable blood-based NfL measurement possible and eliminated the need for a spinal tap in many situations.

Several other platforms now measure blood NfL as well, including Ella, Lumipulse, Elecsys, and high-sensitivity ELISA systems. Values from these platforms correlate strongly with one another, but the raw numbers they produce are not interchangeable. A study comparing Roche Elecsys and Fujirebio Lumipulse measurements found a strong linear relationship between them, but poor absolute agreement. A conversion equation was needed to translate between the two.

³ Simoa remains the most validated platform and is widely considered the reference standard, though a high-sensitivity ELISA has shown reliability as an alternative for labs without access to digital immunoassay equipment.

⁴

This platform variability matters for you as a patient. If your neurologist tracks your NfL over time, the measurements need to come from the same assay platform each time. Switching from one lab’s platform to another mid-stream could make it look like your levels changed when they did not, or mask a real change.

Factors That Shift Your Baseline

Even in completely healthy people, NfL levels are not a single fixed number. Several non-disease factors influence your result, and understanding them helps you avoid misinterpreting a high or low reading.

Age is the biggest one. NfL rises steadily as you get older, reflecting the normal low-grade loss of neurons that accompanies aging. In children, the pattern is more complex: levels are relatively high in infancy, decrease through childhood, reach a low point during adolescence, then begin their slow lifelong climb.

⁵ This means a reading that looks elevated in a 30-year-old might be perfectly normal in a 70-year-old. Any interpretation of NfL needs to be age-adjusted.

Body mass index pulls levels in the opposite direction. Multiple studies have found that higher BMI is associated with lower blood NfL, likely because people with more body mass have a larger blood volume, diluting the NfL concentration.

⁶ Longitudinal data confirm this inverse relationship holds over time and across different measures of body composition.

⁷

Kidney function is another confounder that clinicians have to watch. NfL appears to be at least partly cleared from the blood by the kidneys. When kidney function declines, NfL accumulates, pushing levels higher regardless of whether any nerve damage is occurring. In people with chronic kidney disease, measured glomerular filtration rate was a strong independent predictor of plasma NfL levels, even after accounting for age and other variables.

⁸ A population-based study using U.S. national health survey data confirmed a significant inverse relationship between NfL and estimated kidney filtration rate.

⁹ In practice, this means a high NfL result in someone with impaired kidneys could overestimate the degree of neurological injury.

Multiple Sclerosis

MS is arguably where NfL has found its strongest clinical foothold so far. The test is not used to diagnose MS on its own, since elevated NfL cannot distinguish MS from other causes of nerve damage.

¹⁰ Where it shines is in monitoring. Once you have an MS diagnosis and are on a disease-modifying therapy, the trend in your NfL level over time can signal whether your treatment is working. Stable or falling NfL suggests reduced nerve injury; rising NfL may indicate that the disease is breaking through and a treatment switch should be considered. Higher-efficacy therapies tend to produce larger NfL reductions.

¹¹

ALS and Motor Neuron Disease

Amyotrophic lateral sclerosis produces some of the highest NfL levels of any neurological condition, reflecting the rapid, widespread motor neuron death that characterizes the disease. Blood NfL levels in people with ALS run roughly four times higher than in healthy controls.

¹² Both serum and spinal fluid NfL can distinguish ALS from healthy individuals with high accuracy, and levels at diagnosis are strong independent predictors of survival. Patients in the highest third of NfL at baseline had roughly four times the mortality risk of those in the lowest third.

The prognostic value is one of the most consistent findings in ALS biomarker research. Higher NfL correlates with faster disease progression, higher motor neuron burden scores, and shorter survival across multiple studies.

¹³ However, the picture for diagnosis is less clean. In a real-world referral clinic setting, NfL’s ability to separate ALS from non-ALS neurological conditions was more modest, with sensitivity around 77% at a prespecified cutoff. ALS patients whose NfL fell below the cutoff tended to have slower-progressing forms of the disease.

¹⁴ So while the test adds useful information, it does not replace clinical assessment.

Alzheimer’s Disease and Cognitive Decline

In Alzheimer’s research, NfL serves as a tracker of neurodegeneration rather than of the amyloid plaques that define the disease. Baseline NfL is higher in people with mild cognitive impairment and Alzheimer’s dementia compared to healthy older adults, and the rate of NfL increase over time accelerates as the disease worsens. In one longitudinal study, NfL rose by about 2.4 picograms per liter each year in cognitively healthy controls, 2.7 in people with mild cognitive impairment, and 4.9 in those with Alzheimer’s dementia. Faster NfL increases were tied to accelerated brain shrinkage and declining cognitive scores.

¹⁵

NfL levels also differ between stages when amyloid status is taken into account. Among people with subjective cognitive complaints or mild impairment, those who tested positive for amyloid pathology had higher NfL than amyloid-negative individuals at the same clinical stage.

¹⁶ That said, NfL does not appear to be the earliest blood signal of Alzheimer’s risk. A study following participants for up to 17 years found that GFAP, a marker of astrocyte activation, was associated with clinical Alzheimer’s incidence more than a decade before diagnosis, while NfL and p-tau181 were associated with risk on a more intermediate timeline of about nine years.

¹⁷

Parkinson’s Disease and Related Movement Disorders

In typical Parkinson’s disease, NfL levels are often only mildly elevated or normal. The test becomes far more valuable when clinicians need to tell Parkinson’s apart from its more aggressive cousins, collectively known as atypical parkinsonian disorders. Conditions like progressive supranuclear palsy (PSP), multiple system atrophy, and corticobasal syndrome cause much more rapid and widespread neurodegeneration, and NfL levels tend to be dramatically higher. A head-to-head comparison of assay platforms in over 500 patients with parkinsonism found that NfL had excellent accuracy for distinguishing Parkinson’s from atypical disorders across all tested platforms.

¹⁸ A machine learning study found that combining blood NfL with a brain imaging measurement boosted accuracy even further when separating PSP from Parkinson’s.

¹⁹

Concussion and Traumatic Brain Injury

NfL has drawn particular attention in sports medicine. After a concussion, NfL rises in the blood over the first few days and can help gauge severity. In professional hockey players, NfL levels measured at various time points after a concussion could separate those who needed more than 10 days to return to play from those who recovered faster. Measured at six days post-concussion, NfL was also able to identify players who eventually had to retire due to persistent symptoms.

²⁰

The test may also be useful further out from injury. In a clinic-based cohort that included people with moderate-to-severe traumatic brain injury, serum NfL decreased gradually over five years but remained elevated compared to controls throughout the entire follow-up period.

²¹ That lingering elevation suggests ongoing low-level neurodegeneration long after the initial injury, a finding that has implications for how we think about long-term brain health in athletes and others with head trauma histories.

Stroke and Cerebrovascular Disease

After an ischemic stroke, NfL levels correlate with stroke severity on admission and with the burden of pre-existing white matter damage in the brain. In one study, serum NfL predicted unfavorable outcomes at 90 days post-stroke, independent of other clinical measures.

²² While not yet part of standard stroke workups, NfL could eventually help identify patients at higher risk of poor recovery who might benefit from more aggressive rehabilitation or closer follow-up.

Beyond the Brain

NfL is not exclusively a central nervous system marker. Neurofilaments are present in peripheral nerves too, and damage to those nerves spills NfL into the blood just as brain damage does. In inherited peripheral neuropathies like Charcot-Marie-Tooth disease, plasma NfL is significantly elevated and correlates with clinical disease severity.

²³ In vasculitic neuropathy, serum NfL correlated specifically with histological markers of acute axonal degeneration in nerve biopsies, though not with chronic axonal loss.

²⁴ A regression analysis of focal lesions across various conditions confirmed that brainstem and peripheral nerve damage were both independently associated with high NfL levels.

²⁵

This peripheral sensitivity cuts both ways. It broadens the test’s utility beyond pure brain diseases, but it also means that an elevated NfL in someone with both a brain condition and a peripheral neuropathy may be hard to attribute to one or the other.

The Test in Drug Development

Pharmaceutical companies have embraced NfL as a tool for measuring whether experimental drugs are actually slowing nerve damage. Between 2005 and 2024, 50 investigational drug programs submitted to the U.S. FDA proposed using NfL in some capacity. The vast majority used it to track the drug’s biological effect on neurodegeneration, while about half also used it to sort patients into subgroups, and a fifth proposed it as a surrogate endpoint that could support accelerated approval.

²⁶

The logic is straightforward: if an Alzheimer’s drug reduces NfL, that provides evidence it is slowing neuronal death, even before clinical benefits become measurable on cognitive tests. In one recent Alzheimer’s trial, an oral drug called valiltramiprosate produced significantly lower plasma NfL than placebo at 78 weeks in patients with mild cognitive impairment, and the NfL stability correlated with improvements on cognitive tests and less hippocampal shrinkage.

²⁷

That said, the relationship between NfL changes and clinical outcomes is not always in lockstep. A scoping review of trials across neurodegenerative diseases found that NfL reductions often paralleled improvements in primary outcomes, but several studies showed a disconnect. Some drugs lowered NfL without producing clinical benefit, and the mismatch was more common when the drug’s mechanism was symptomatic rather than disease-modifying.

²⁸

Practical Limitations

The biggest limitation is one that runs through every section above: NfL is not disease-specific. An elevated result tells your doctor that neurons are being damaged somewhere in your nervous system. It does not say why. A high reading could reflect MS, Alzheimer’s, a recent concussion, a peripheral neuropathy, or simply reduced kidney function in an older patient. On its own, it lacks both the sensitivity and specificity to serve as a standalone diagnostic test for any single condition.

²⁹

Access is another barrier. The ultrasensitive assay platforms required are not standard equipment in most hospital laboratories. Testing is often restricted to specialized reference labs or research centers, and the cost per assay remains relatively high.

³⁰ Insurance coverage varies and is still evolving, particularly in the United States.

The lack of universal reference ranges also complicates clinical interpretation. Because different assay platforms produce different absolute values and because age, BMI, and kidney function all shift the baseline, a single cutoff that means “abnormal” for everyone does not exist. Clinicians typically interpret NfL in context, looking at trends over time within the same patient using the same assay, rather than comparing a one-time result to a fixed threshold.

NfL in Children

Pediatric neurology is a newer frontier for NfL testing, and the reference ranges look different from adults. In a large Canadian pediatric cohort, the normal range for children aged 1 to 10 was roughly 3 to 21 picograms per milliliter, while for adolescents aged 10 to 18 it narrowed to about 2 to 7.

⁵ The higher levels in young children likely reflect the intense period of brain development and neuronal pruning happening during those years.

Interestingly, a study examining NfL in children with various acute and chronic neurological conditions found no significant differences between sick children and healthy controls, including those with febrile seizures and epileptic seizures.

³¹ Whether this reflects the types of conditions studied, the resilience of the developing nervous system, or limitations in sample size remains unclear. The clinical utility of NfL in children is still an open question, and results should be interpreted cautiously.

The Ethics of Knowing Early

As NfL becomes more available, a difficult question emerges for people at genetic risk for neurodegenerative diseases: do you want to know that nerve damage has started before symptoms appear? In genetic frontotemporal dementia, for instance, NfL can rise years before clinical onset. Researchers studying at-risk family members have grappled with whether and how to disclose these results. Some participants value the information because it helps them plan for the future and reduces uncertainty. Others find it psychologically distressing to learn that a disease process may have begun when they still feel healthy.

³²

This tension is not unique to NfL, but the test’s increasing accessibility brings it closer to everyday medical practice. Unlike genetic tests, which reveal fixed risk, NfL reflects an active biological process. An elevated level does not just say you carry a gene; it suggests something is happening now. That immediacy can be both informative and destabilizing, and the frameworks for counseling patients around these results are still being developed.